The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis

Respiratory Medicine

Volumn 93, Issue 4, 1999, Pages 252-261

  Read, R C ^a   Kuss, A ^b   Berrisoul, F ^c   Kearsley, N ^d   Torres, A ^e   Kubin, R ^f  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b Richmond Medical Centre ^*  (Germany)

^c Hospital Clinic ^*  (France)

^d Richmond Medical Centre   (United Kingdom)

^e HOSPITAL CLÍNIC   (Spain)

^f Bayer plc UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACTERIUM ISOLATION; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUS; RANDOMIZED CONTROLLED TRIAL; SPUTUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SUSPENSION; TABLET;

EID: 0032942125     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(99)90021-5     Document Type: Article

References (45)

1. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108: 43S-52S.
2. Orr PH, Scherer K, Macdonald A, Moffatt ME. Randomized, placebo-controlled trials of antibiotics for acute bronchitis: a critical review of the literature. J Fam Pract 1993; 36: 507-512.
3. Johnson JA. Pathogenesis of bacterial infections of the respiratory tract. Br J Biomed Sci 1995; 52: 157-161.
4. Mulder J, Goslings WRO, Vaan der Plas MC, Lopes Cardozo P. Studies on the treatment with antibacterial drugs of acute and chronic purulent bronchitis caused by Haemophilus influenzas. Acta Med Scand 1952; 142: 32-49.
5. Baquero F, Loza E. Antibiotic resistance of microorganisms involved in ear, nose and throat infections. Pediatr Infect Dis 1994; 18: S9-S14.
6. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990; 34: 2075-2080.
7. Kayser FH, Morenzoni G, Santanam P. The Second European Study on the frequency of antimicrobial resistance in Haemophilus influenzae. Eur J Clin Microbiol Infect Dis 1990; 9: 810-817.
8. Kobayashi H, Takamure H, Takeda H et al. Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections. Chemother (Tokyo) 1986; 34: 1011-1037.
9. Chodosh S, Tuck J, Stottmeier KD, Pizzuto D. Comparison of ciprofloxacin with ampicillin in acute infec-tious exacerbations of chronic bronchitis. Am J Med 1989; 87 (Suppl. 5A): 107-112.
10. Schmidt EW, Zimmermann I, Ritzerfeld W, Voss E, Ulmer WT. Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1989; 24 (Suppl. B): 185-193.
11. Basran GS, Joseph J, Abbas AMA, Hughes C, Tillotoson G. Treatment of acute exacerbations of chronic obstructive airways disease - a comparison of amoxycillin and ciprofloxacin. J Antimicrob Chemother 1990; 26 (Suppl. F): 19-24.
12. Cazzola M, Vinciguerra A, Beghi GF et al. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J Chemother 1995; 7: 432-441.
13. Chodosh S, Echols R, Kowalsky S, Painter B, Valalik E. A prospective, randomized, double-blind, comparative study of ciprofloxacin and cefuroxime axetil for the treatment of acute exacerbations of chronic bronchitis. Ann Meet Infect Dis Soc Am, 1995; Washington DC, USA. A166 (Abstract).
14. Chodosh S, Schreurs AJM, Shan M, Moesker HL, Kowalsky S, The Bronchitis Study Group. The efficacy of oral ciprofloxacin vs clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1996; 23: 913. (Abstract).
15. Anzueto A, Niederman MS, Haverstock DC, Tillotson G, The Bronchitis Study Group. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Clin Therapeut 1997; 19: 55-67.
16. The Canadian Ciprofloxacin Health Economic Study Group, Grossman R, Mukherjee J et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998; 113: 131-141.
17. Bergan T, Thorsteinsson SB, Solberg S, Bjornskau L, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med 1987; 82 (Suppl. 4A): 97-102.
18. Bergogne-Bérézin E. Pharmacokinetics of fluoroquinolones in the respiratory tissues and fluids. Quin Bull 1993; 10: 1-5.
19. Hooper DC, Wolfson JS. Mechanisms of quinolone action and bacterial killing. In: Hooper DC, Wolfson JC, eds. Quinolone Antimicrobial Agents. Washington DC: American Society for Microbiology, 1993, 53-75.
20. NCCLS. Performance standards for antimicrobial susceptibility testing. Wayne, USA: National Committee for Clinical Laboratory Standards; 1990. Document M100-S6.
21. Baquero F, Alvarez M-E, Cantón R. Bacteriological diagnosis of respiratory tract infections. Clin Microbiol Infect 1996; 1: S10-S15.
22. Aigner K, Schindl R, Mittermayer H. Augmentin in acute exacerbations of chronic bronchitis. J Int Med Res 1984; 12: 321-326.
23. McGhie D, Kerfoot P, Talbot DJ. A comparative study of Miraxid (pivmecillinam plus pivampicillin) and Augmentin (amoxycillin plus clavulanic acid) in the treatment of lower respiratory tract infections in general practice. J Int Med Res 1986; 14: 254-260.
24. Maesen FP, Davies BI, Baur C. Amoxycillin/ clavulanate in acute purulent exacerbations of chronic bronchitis. J Antimicrob Chemother 1987; 19: 373-383.
25. Periti P, Novelli A, Schildwachter G, Schmidt-Gayk H, Ryo Y, Zuck P. Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. J Antimicrob Chemother 1990; 26 (Suppl. E): 63-69.
26. Rademaker CM, Sips AP, Beumer HM et al. A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1990; 26 (Suppl. D): 75-81.
27. Legnani D, Lombardo VM, Negretto GG, Beghi G, Caratozzolo O. Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. J Hosp Infect 1992; 22 (Suppl. A): 69-74.
28. Beghi G, Berni F, Carratu L et al. Efficacy and tolerability of azithromycin versus amoxicillin/ clavulanic acid in acute purulent exacerbations of chronic bronchitis. J Chemother 1995; 7: 146-152.
29. Behler PG, Boge K, Bohning W, Gams W, Gartner-Toth M, Wettengel R. Amoxicillin/clavulanic acid vs cefetamet pivoxil in the treatment of acute exacerbation of chronic bronchitis (AECB) in adults. J Chemother 1995; 7 (Suppl. 1): 16-20.
30. Aubier MA. Comparison of ceftibuten versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Chemother 1997; 43: 297-302.
31. Hoepelman IM, Mollers MJ, van Schie MH et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (coamoxiclav) in the treatment of adults with lower respiratory tract infections and effect on long-term outcome. Int J Antimicrob Agents 1997; 9: 141-146.
32. Ball AP. Evidence for the efficacy of ciprofloxacin in lower respiratory tract infections. Rev Contemp Pharmacother 1992; 3: 133-142.
33. Ball AP, Tillotson GS. Lower respiratory tract infection therapy - the role of ciprofloxacin. J Int Med Res 1995; 23: 315-327.
34. Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother 1998; 42: 114-120.
35. Cazzola M, Matera MG. Interrelationship between pharmacokinetics and pharmacodynamics in choosing the appropriate antibiotic and the dosage regimen for treating acute exacerbations of chronic bronchitis. Respir Med 1998; 92: 895-901.
36. Nix DE, Schentag JJ. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics. Diagn Microbiol Infect Dis 1995; 22: 71-76.
37. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108: 835-840.
38. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; 74 (Suppl.): 63-70.
39. Drusano GL, Craig WA. Relevance of pharmaco-kinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 (Suppl. 3): 38-44.
40. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
41. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 157: 831-847.
42. Leggett JE, Fantin B, Ebert S et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-292.
43. Craig WA. The pharmacokinetics of cefpirome: rationale for a twelve-hour dosing regimen. Scand J Infect Dis 1993; 91 (Suppl.): 33-40.
44. Smith JT. Awakening the slumbering potential of the 4-quinolone antibacterials. Pharm J 1984; 233: 299-305.
45. Chin N, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1984; 25: 319-326.